2017-06-302026-03-272017-06-302005María Teresa Cordero Ortíz0028-390810.1016/j.neuropharm.2005.03.020https://doi.org/10.1016/j.neuropharm.2005.03.020https://repositorio.inprf.gob.mx/handle/123456789/6767engacceso cerrado5-Methoxytryptamine-Analogs & derivatives5-Methoxytryptamine-Pharmacology8-Hydroxy-2-(di-n-propylamino) tetralin-PharmacologyAmygdalaAnimalsAnticonvulsantsConvulsantsDose-Response Relationship, DrugEpilepsy, Complex Partial-Prevention & controlEpilepsy, Generalized-Drug therapyEpilepsyGeneralized-PhysiopathologyEpilepsy, Tonic-Clonic-Drug therapyEpilepsy, Tonic-Clonic-PhysiopathologyExcitatory Amino Acid AgonistsKainic AcidKindling, NeurologicMalePentylenetetrazoleRatsRats, WistarReceptor, Serotonin, 5-HT1A-Drug effectsSeizures-Drug therapySerotonin Receptor Agonists-PharmacologyStatus Epilepticus-Chemically Induced StatusEpilepticus-Prevention & controlarticle1873-70643Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz367-375Inglaterra498-OH-DPATIndorenate5-HT1A receptor agonistPentylenetetrazoleKainic acidAmygdala kindlingPostictal depression8-OH-DPATIndorrenatoAgonista de los receptores 5-HT1APentilentetrazolÁcido kaínicoAmígdala kindlingDepresión postictal